Coherus BioSciences Inc (CHRS)
2.23
-0.02
(-0.89%)
USD |
NASDAQ |
May 08, 16:00
2.23
0.00 (0.00%)
Pre-Market: 20:00
Coherus BioSciences Gross Profit Margin (Quarterly): 7.60% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.60% |
| September 30, 2023 | 56.14% |
| June 30, 2023 | 57.68% |
| March 31, 2023 | 47.98% |
| December 31, 2022 | 68.68% |
| September 30, 2022 | 22.43% |
| June 30, 2022 | 81.25% |
| March 31, 2022 | 84.41% |
| December 31, 2021 | 83.50% |
| September 30, 2021 | 74.21% |
| Date | Value |
|---|---|
| June 30, 2021 | 80.95% |
| March 31, 2021 | 90.95% |
| December 31, 2020 | 89.43% |
| September 30, 2020 | 92.07% |
| June 30, 2020 | 92.53% |
| March 31, 2020 | 94.10% |
| December 31, 2019 | 93.70% |
| September 30, 2019 | 94.23% |
| June 30, 2019 | 99.28% |
| March 31, 2019 | 94.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
7.60%
Minimum
Dec 2023
99.28%
Maximum
Jun 2019
74.27%
Average
83.50%
Median
Dec 2021
Gross Profit Margin (Quarterly) Benchmarks
| AbbVie Inc | 66.74% |
| Inovio Pharmaceuticals Inc | -- |
| Nektar Therapeutics | 69.51% |
| Avid Bioservices Inc | 7.05% |
| Stereotaxis Inc | 59.98% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -46.35% |
| Return on Invested Capital | -77.98% |
| Profit Margin (Quarterly) | -87.03% |
| Operating Margin (Quarterly) | -75.29% |
| Return on Net Operating Assets | -86.78% |